SCHEMBL5832076

SCHEMBL5832076

CONC(=O)c1nccc2ncn(Cc3ccc(F)cc3)c12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP13 P45452 3/20 0.45
CYP11B1 P15538 1/20 0.42
CYP11B2 P19099 1/20 0.42
MAPK14 Q16539 1/20 0.41
HSD17B13 Q7Z5P4 1/20 0.40
HSP90AA1 P07900 1/20 0.40
HSP90B1 P14625 1/20 0.40
GAA P10253 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
RAB9A P51151 1/20 0.39
EGLN1 Q9GZT9 1/20 0.38
LMNA P02545 2/20 0.38
PKM P14618 1/20 0.38
TSHR P16473 1/20 0.38
HDAC3 O15379 1/20 0.38
HDAC4 P56524 1/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC7 Q8WUI4 1/20 0.38
HDAC2 Q92769 1/20 0.38
HDAC10 Q969S8 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4903920 0.89 HSP90AA1 (0.47) MMP13CYP11B1CYP11B2MAPK14HSD17B13
SCHEMBL4909246 0.84 EGLN1 (0.44) MMP13HSD17B13RAB9AEGLN1LMNA
SCHEMBL1684151 0.80 MMP13 (0.36) MMP13MAPK14HSD17B13HSP90AA1HSP90B1
SCHEMBL2951434 0.75 MMP13 (0.48) MMP13CYP11B1CYP11B2HDAC1HDAC6
SCHEMBL4904745 0.74 EGLN1 (0.53) MMP13CYP11B1CYP11B2MAPK14HSP90AA1
SCHEMBL4804260 0.72 EGLN1 (0.47) GAAL3MBTL1EGLN1
SCHEMBL4914229 0.71 HDAC6 (0.48) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL20591088 0.69 CYP11B2 (0.48) CYP11B1CYP11B2HSP90AA1HSP90B1GAA
SCHEMBL27244146 0.69 CYP11B2 (0.45) MMP13CYP11B1CYP11B2L3MBTL1LMNA
SCHEMBL28430515 0.67 PKM (0.57) CYP11B1CYP11B2HSP90AA1HSP90B1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7135482-B2 HIV-integrase inhibitors, pharmaceutical compositions, and methods for their use AGOURON PHARMACEUTICALS, INC. (US) 2006-11-14 US disclosed
US-20040147547-A1 HIV-integrase inhibitors, pharmaceutical compositions, and methods for their use AGOURON PHARMACEUTICALS, INC. 2004-07-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147547-A1 HIV-integrase inhibitors, pharmaceutical compositions, and methods for their use IMPDH1, POLA1, POLB MMP13 1251/4885CYP11B1 975/4885CYP11B2 1512/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.